€13m brings glimin of hope for Poxel in type 2 diabetes
This article was originally published in Scrip
Poxel, a Merck Serono spin-off company based in France, will use €13 million raised in a series B financing round to prepare its novel first-in-class oral anti-diabetic, imeglimin, for Phase III studies.
You may also be interested in...
Meindert Boysen, head of NICE’s Centre For Health Technology Evaluation, shares advice for companies aiming to get their medicine to patients. His golden rules: engage in early advice and be more realistic about pricing.
Softening provisions to make EU-wide joint clinical assessments voluntary would make proposed legislation on HTA cooperation redundant, says Eurordis.
Plans for EU-wide Joint Clinical assessments will come under scrutiny at an EU council meeting next week.